June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Got $500? 3 Under $10 Stocks You Can Buy Right Now!

Published 2021-07-28, 04:03 p/m
Got $500? 3 Under $10 Stocks You Can Buy Right Now!
CRH
-

Investing in the equity markets remains the best way to create long-term wealth as interest rates remain near record lows and inflation numbers keep rising. However, several indexes are trading near record highs driven by the impressive rally in tech stocks.

But if you look closer there are several lower-priced stocks trading at an attractive valuation and have the potential to increase your savings exponentially.

You do not need a significant amount of capital to gain exposure to lower-priced stocks and can better diversify your portfolio as a result. Here, we look at three such stocks that are trading below $10.

WELL Health The first stock on my list is WELL Health Technologies (TSX:WELL), a digital health company valued at a market cap of $1.47 billion. WELL stock has gained a monstrous 7,150% in just over five years turning an investment of $500 into $36,000 in this period.

Despite these market-thumping gains, WELL stock remains undervalued. WELL Health has managed to increase its sales from $5.9 million in 2018 to $50.14 million in 2020 on the back of several accretive acquisitions.

This trend will continue in the near term given WELL’s recent acquisition of CRH (LON:CRH) Medical this year. Now, Bay Street expects WELL sales to rise over 425% year over year to $265 million in 2021 and by 60% to $423 million in 2022. This will allow the company to improve its bottom line from a loss per share of $0.03 in 2020 to earnings of $0.06 in 2022.

Analysts have a 12-month average price target of $12 for WELL stock, which is 55% above its current price.

4Front Ventures A small-cap U.S.-based cannabis manufacturer, 4Front Ventures (CNSX:FFTN) is valued at a market cap of $1.08 billion with a share price of $1.46. The company aims to gain traction in cannabis markets such as Washington, Illinois, Michigan, California, and Massachusetts.

It has reported a positive cash flow since August 2020 and a positive adjusted EBITDA in Q3 of 2020. In fiscal 2021, the marijuana producer has estimated sales between US$170 million and US$180 million with adjusted EBITDA between US$40 million and US$50 million.

4Front Ventures is part of a rapidly expanding addressable market and will benefit from multiple secular tailwinds in the upcoming decade. It forecast global cannabis spending to touch US$20.4 billion in 2020, a rise of 38% year over year. Comparatively, it also expects the U.S. cannabis market to be valued at US$35 billion by 2024, up from US$12.4 billion in 2019.

Gage Growth A micro-cap stock valued at a market cap of $330 million, Gage Growth (CSE:GAGE) is the final company on my list. Gage Growth has a significant presence in Michigan, a state with a population of 10 million. Michigan’s adult-use cannabis sales touched $985 million in 2020 and in March monthly sales stood at $146 million, indicating an annualized run rate of $1.8 billion for 2021.

Gage Growth has already grown its sales from $1.92 million in 2019 to $39.88 million in 2020. In the first quarter of 2021, Gage Growth reported sales of $17.6 million which suggests total sales might surpass $70 million in 2021.

So, Gage Growth stock is valued at a forward price to sales multiple of less than 5 which is very reasonable for a high-growth company.

The post Got $500? 3 Under $10 Stocks You Can Buy Right Now! appeared first on The Motley Fool Canada.

This Article Was First Published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.